LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. (Q54020050)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. |
scientific article |
Statements
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. (English)
1 reference
S Ramalingam
1 reference
J C-H Yang
1 reference
C K Lee
1 reference
T Kurata
1 reference
D-W Kim
1 reference
T John
1 reference
N Nogami
1 reference
Y Ohe
1 reference
P A Jänne
1 reference
15 April 2016
1 reference
11
1 reference
4 Suppl
1 reference
S152
1 reference